Spironolactone in Alcohol Use Disorder (SAUD)

Abroad (travel likely)RecruitingPHASE1

Conditions

Alcohol Use Disorder

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

National Institute on Drug Abuse, Baltimore, Maryland, United States
Contact: Study coordinator (Lorenzo Leggio, M.D.) · lorenzo.leggio@nih.gov · 240-478-1503
Contact: Study coordinator (Masoumeh Dejman) · masoumeh.dejman@nih.gov · (240) 987-8983

Study leads

Lorenzo Leggio, M.D.
Principal Investigator
National Institute on Drug Abuse (NIDA)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Cannabidiol and Alcohol Use Disorder Phenotypes

Alcohol Use Disorder

Abroad (travel likely)RecruitingPHASE2

Aurora, United States

PET Imaging of Phosphodiesterase-4B (PDE4B) in Alcohol Use Disorder

Alcohol Use Disorder

Abroad (travel likely)RecruitingPHASE1

Bethesda, United States

Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)

Alcohol Use Disorder

Abroad (travel likely)RecruitingPHASE1

Bethesda, United States

Alcohol Use Disorder and Cannabidiol

Alcohol Use Disorder

Abroad (travel likely)RecruitingPHASE2, PHASE3

Aurora, United States